Domenico Mario Giamundo

Main Lessons of the Recent Andexanet Withdrawal karger.com/crd/article-ab…

Pubmed article 20 for 2026. Grateful to all coauthors for the collaboration. A perfect mix of hungry rising stars and international experts ☀️

Main Lessons of the Recent #AndexanetWithdrawal karger.com/crd/article-ab…

karger.com/crd/article-ab… Thanks to @AtarDan @jamundus20 and @MarcoBernardiMD

@RCMjournal A heartfelt thank you to Prof @SABOURETCardio and Prof @mmamas1973

The latest work from Sorbonne Université by first author Prof. Pierre F. SABOURET and his team is now featured in RCM! 👉 Explore the full study: imrpress.com/journal/RCM/27… Article Highlights 💡 Does the clinical benefit of PCSK9 inhibitors truly depend on the drug type, or is it primarily driven by baseline LDL-C and patient risk profile? 💡 Why do trials like ODYSSEY OUTCOMES and FOURIER appear to show different patterns of benefit across LDL-C strata, and what explains these differences in real-world interpretation? 💡 Should alirocumab and evolocumab be considered clinically distinct, or are observed differences mainly a reflection of baseline risk, trial design, and treatment strategy rather than drug-specific biology? ✒️ Authors: Pierre Sabouret @SABOURETCardio (Corresponding author), Domenico Mario Giamundo @jamundus20 , Mamas Mamas @mmamas1973 🏪 Affiliation: Sorbonne University, “Tor Vergata” University @unitorvergata, University Hospitals of North Midlands NHS Trust, Keele University @KeeleUniversity 📖 Don’t miss this citable reference for your future research! Citation format: Pierre Sabouret, Domenico Mario Giamundo, Mamas Mamas. Focus on Baseline LDL-C and Patient Risk, Not Drug Type: A Perspective on Alirocumab vs Evolocumab. Rev. Cardiovasc. Med. 2026, 27(4), 50430. Welcome to submit your work via our submission link👉: imr.propub.com RCM welcomes review papers, research articles and other types of research in both cardiovascular medicine and cardiovascular disease. 📖 Click here for author guidelines: imrpress.com/journal/RCM/pa… #PCSK9Inhibitors #LDLCholesterol #CardiovascularRisk #Dyslipidemia #AtheroscleroticCardiovascularDisease

Is the benefit of #PCSK9 #inhibitors driven by the #drug itself—or by baseline #LDL-C and patient risk? Prof. @SABOURETCardio and team explore key insights from ODYSSEY OUTCOMES vs FOURIER and clinical implications. imrpress.com/journal/RCM/27… #Cardiovascular #Atherosclerosis

@SABOURETCardio @Twinkle_IMR @RCMjournal The correct link is this: lnkd.in/grc4asYt

@Twinkle_IMR @jamundus20 @RCMjournal Dear @Twinkle_IMR, is the link adequate ? Kind regards

Thanks to @mmamas1973 and @jamundus20 for this new collaboration. FREE ACCESS @Meriem_ghozzia @DMFrontiers @paola_pastena @juliopaslopz @PatrickEllswo15 @g_matheusg @EAS_Society @pabeda1 @STavaresSara @stecacMD @luisrsilveira @DrIvanLucas @inespinedatorra @Pooh_Velagapudi

#MA #PCSK9i imrpress.com/journal/RCM/27…

frontiersin.org/journals/radio… #CACScore #CVR

Pubmed article with pdf available. #Andexanet withdrawal. Thanks to coauthors #DanAtar #MarioDomenicoGiamundo #MarcoBernardi #Cardiology journal #Karger

Our article on #CACscore has been accepted ☀️ grateful of this new collaboration with friends and experts

Wake up with a good news as our article is accepted. Thanks to all coauthors for their contributions ☀️

Our article on #Andexanet withdrawal is online. Thanks again to #DanAtar @MarcoBernardiMD #DomenicoMarioGiamundo ☀️ #Karger

À good news with a new accepted pubmed article. Thanks to the worldwide expert #DanAtar and the rising stars #DomenicoMarioGiamundo @MarcoBernardiMD @LuigiSpadafora ☀️

Thanks to #RCM #IMRpress for the invitation. A pleasure to collaborate again with @mmamas1973 and @jamundus20 #PCSK9i #ACS #CCS #MVD